Skip to main content
Friulchem logo

Friulchem — Investor Relations & Filings

Ticker · FCM ISIN · IT0005378457 LEI · 8156003DC8C04217A094 XMIL Manufacturing
Filings indexed 69 across all filing types
Latest filing 2023-03-23 Earnings Release
Country IT Italy
Listing XMIL FCM

Friulchem is a Contract Development and Manufacturing Organization (CDMO) dedicated to the Animal Health sector. The company provides integrated services that cover the research, development, and production of veterinary products. Its manufacturing capabilities include micronization, granulation, mixing, spray drying, and packaging. Friulchem produces a range of items, including pharmaceuticals, food supplements, complementary feeds, and premixes for both livestock and companion animals. The company utilizes proprietary drug delivery technologies to develop customized formulations. A key product is Fc-Cubes®, a highly palatable chewable tablet for pets, which is part of its Suppleo brand of complementary foods.

Recent filings

Filing Released Lang Actions
IL CONSIGLIO DI AMMINISTRAZIONE DI FRIULCHEM HA APPROVATO IL PROGETTO DI BILANCIO E IL BILANCIO CONSOLIDATO AL 31 DICEMBRE 2022
Earnings Release Classification · 98% confidence The document is titled 'COMUNICATO STAMPA' (Press Release) and prominently features key financial figures for the year ended December 31, 2022, including Revenue, EBITDA, Net Income, and Net Financial Position, for both the consolidated group and the parent company. It explicitly states that the Board of Directors approved the 'Progetto di Bilancio e il bilancio consolidato al 31 dicembre 2022' (Draft Financial Statements and Consolidated Financial Statements as of December 31, 2022). This structure—a press release summarizing annual financial results—is characteristic of an Earnings Release (ER). While it contains detailed financial data, its primary function here is the initial announcement of the annual results, not the full statutory filing (10-K) or a comprehensive interim report (IR). Furthermore, it announces the date for the Ordinary Shareholders' Meeting, which is typical context provided alongside annual results announcements. Given the focus on summarizing the annual financial performance immediately following board approval, ER is the most appropriate classification. FY 2022
2023-03-23 Italian
CALENDARIO EVENTI SOCIETARI 2023
Report Publication Announcement Classification · 95% confidence The document is titled "CALENDARIO EVENTI SOCIETARI 2023" (Corporate Events Calendar 2023) and lists scheduled dates for key corporate activities throughout the year, such as Board Meetings for approving the Annual Financial Statements and shareholder meetings (Assemblea Ordinaria) for approval. This type of forward-looking schedule announcement, which informs investors about future reporting and meeting dates, is best classified as a general corporate announcement. Since it is not a specific report (like 10-K, ER, or IR) but an announcement about future corporate events, and it doesn't fit the specific definitions for DIRS, DIV, or MANG, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory disclosures not covered elsewhere. The document length is short (3221 chars) and it is purely informational regarding a schedule.
2022-12-19 Italian
FRIULCHEM, ATTRAVERSO LA SUA CONTROLLATA FC FRANCE ACQUISISCE IL 70% DI ARCANATURA
M&A Activity Classification · 99% confidence The document is explicitly titled "COMUNICATO STAMPA" (Press Release) and details a significant corporate transaction: Friulchem's subsidiary acquiring a stake in Arcanatura and a capital increase in FC France. This type of announcement, detailing M&A activity, financing, and strategic development via a press release format, is generally classified as a general regulatory announcement or a specific transaction announcement. Since the core event is an acquisition/financing related to corporate structure and growth, it aligns best with Capital/Financing Update (CAP) or M&A Activity (TAR). Given the dual nature (acquisition of a company AND capital increase), and the fact that it is a press release announcing the event rather than the formal regulatory filing (like a 10-K or a detailed M&A disclosure), it fits well under the general announcement category if a more specific one isn't perfect. However, the primary driver is the acquisition and capital strengthening to support growth. Since 'TAR' (M&A Activity) covers merger proposals or takeover bids, and this is an acquisition, it is a strong candidate. 'CAP' (Capital/Financing Update) also fits due to the capital increase. Given the emphasis on the acquisition of 70% of Arcanatura, TAR is slightly more specific to the main event. If TAR is interpreted strictly as a takeover bid, then CAP might be safer, but acquisitions are often grouped under M&A. Since this is a definitive announcement of an acquisition, TAR is the most appropriate specific code. If TAR is too narrow, RNS (Regulatory Filings) would be the fallback, but TAR covers the core event.
2022-12-19 Italian
“WARRANT FRIULCHEM S.P.A. 2019-2022” - ISIN IT0005378366 CHIUSURA DEL TERZO E ULTIMO PERIODO DI ESERCIZIO 1-30 NOVEMBRE 2022
Capital/Financing Update Classification · 99% confidence The document is a press release ("COMUNICATO STAMPA") dated December 1, 2022, announcing the conclusion of the third and final exercise period for the company's Warrants ("WARRANT FRIULCHEM S.P.A. 2019-2022"). It explicitly states that no warrants were exercised during the period (November 1 - November 30, 2022) and that the warrants will lapse. This is a specific corporate action announcement related to financing instruments (warrants) and capital structure, rather than a full financial report (10-K, IR) or a general earnings release (ER). It fits best under Capital/Financing Update (CAP) as it details the outcome of a financing instrument exercise period, or potentially Regulatory Filing (RNS) if it were a generic announcement. Given the specific nature regarding warrants and exercise periods, CAP is the most precise fit, as it relates directly to capital structure changes/outcomes. The document length is short (2991 chars), but it is providing substantive information about the warrant expiration, not just announcing that a report is available.
2022-12-01 Italian
“WARRANT FRIULCHEM S.P.A. 2019-2022” - ISIN IT0005378366 APERTURA DEL TERZO E ULTIMO PERIODO DI ESERCIZIO 1-30 NOVEMBRE 2022
Capital/Financing Update Classification · 98% confidence The document is a press release ("COMUNICATO STAMPA") announcing the opening of the third and final exercise period (November 1-30, 2022) for the 'Warrant Friulchem S.p.A. 2019-2022'. This announcement details the terms for exercising warrants to subscribe for new shares ('Azioni di Compendio') at a specified price. This activity directly relates to the company's capital structure and the issuance/exercise of securities, which falls under Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate finance event.
2022-10-28 Italian
Il Consiglio di Amministrazione di Friulchem ha approvato la Relazione Consolidata Semestrale al 30 giugno 2022
Report Publication Announcement Classification · 95% confidence The document is a press release from Friulchem S.p.A. announcing the approval of its consolidated half-year financial report as of June 30, 2022. It provides key financial highlights (revenue, EBITDA, net financial position) and includes summary financial tables (income statement, balance sheet). While it contains financial data, it is structured as a corporate announcement (press release) rather than the full, formal interim report itself. According to the 'Menu vs Meal' rule, this is an announcement of the report's publication, which falls under the category of Report Publication Announcement (RPA). H1 2022
2022-09-23 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.